Oglemilast |
| Catalog No.GC36793 |
L'oglémilast (GRC 3886) est un inhibiteur de la phosphodiestérase-4 (PDE4) puissant et actif par voie orale avec une IC50 de 0,5 nM pour la PDE4D3.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 778576-62-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Oglemilast(GRC3886) is a potent PDE4 inhibitor, under clinical studies in the treatment of allergen-induced asthma.IC50 value:Target: PDE4
[1]. Giembycz MA. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking• Br J Pharmacol. 2008 Oct;155(3):288-90. [2]. Study of Oglemilast for the Prevention of Asthma. [3]. Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD) [4]. Study of Oglemilast for the Treatment of Asthma
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *